Celyad SA (CYAD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Celyad SA (CYAD) has a cash flow conversion efficiency ratio of 0.177x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.85 Million ≈ $-3.33 Million USD) by net assets (€-16.12 Million ≈ $-18.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Celyad SA - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Celyad SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Celyad SA for a breakdown of total debt and financial obligations.
Celyad SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celyad SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Comprehensive Healthcare Systems Inc
V:CHS
|
-0.033x |
|
Soc Franc Casinos
PA:SFCA
|
0.092x |
|
Locate Technologies Ltd
AU:LOC
|
-0.104x |
|
Kesla Oyj A
HE:KELAS
|
0.068x |
|
Lions Bay Capital Inc
V:LBI
|
-0.152x |
|
BAIYU Holdings Inc.
NASDAQ:BYU
|
-0.009x |
|
EXCELLENCE S.A. ZY -10
F:8XY
|
0.086x |
|
Terragen Holdings Ltd
AU:TGH
|
-0.330x |
Annual Cash Flow Conversion Efficiency for Celyad SA (2010–2024)
The table below shows the annual cash flow conversion efficiency of Celyad SA from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see Celyad SA market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-16.12 Million ≈ $-18.85 Million |
€-5.68 Million ≈ $-6.64 Million |
0.352x | +114.61% |
| 2023-12-31 | €6.30 Million ≈ $7.37 Million |
€-15.20 Million ≈ $-17.77 Million |
-2.411x | +62.83% |
| 2022-12-31 | €4.32 Million ≈ $5.05 Million |
€-28.01 Million ≈ $-32.75 Million |
-6.488x | -962.73% |
| 2021-12-31 | €43.64 Million ≈ $51.02 Million |
€-26.64 Million ≈ $-31.15 Million |
-0.611x | +31.60% |
| 2020-12-31 | €30.99 Million ≈ $36.24 Million |
€-27.66 Million ≈ $-32.34 Million |
-0.893x | -44.38% |
| 2019-12-31 | €45.62 Million ≈ $53.33 Million |
€-28.20 Million ≈ $-32.97 Million |
-0.618x | -26.12% |
| 2018-12-31 | €55.59 Million ≈ $64.99 Million |
€-27.25 Million ≈ $-31.86 Million |
-0.490x | +52.97% |
| 2017-12-31 | €47.53 Million ≈ $55.57 Million |
€-49.55 Million ≈ $-57.93 Million |
-1.042x | -283.66% |
| 2016-12-31 | €90.88 Million ≈ $106.25 Million |
€-24.69 Million ≈ $-28.87 Million |
-0.272x | -10.92% |
| 2015-12-31 | €111.47 Million ≈ $130.32 Million |
€-27.30 Million ≈ $-31.92 Million |
-0.245x | +62.47% |
| 2014-12-31 | €26.68 Million ≈ $31.20 Million |
€-17.41 Million ≈ $-20.36 Million |
-0.653x | -3.66% |
| 2013-12-31 | €16.90 Million ≈ $19.76 Million |
€-10.64 Million ≈ $-12.44 Million |
-0.630x | -109.91% |
| 2012-12-31 | €-1.31 Million ≈ $-1.53 Million |
€-8.34 Million ≈ $-9.75 Million |
6.352x | +169.92% |
| 2011-12-31 | €840.11K ≈ $982.18K |
€-7.63 Million ≈ $-8.92 Million |
-9.084x | -848.39% |
| 2010-12-31 | €8.69 Million ≈ $10.16 Million |
€-8.32 Million ≈ $-9.73 Million |
-0.958x | -- |
About Celyad SA
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding … Read more